Henn Matthew R 4
4 · Seres Therapeutics, Inc. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Seres (MCRB) President Matthew R. Henn Receives 75,000-Share Award
What Happened
Matthew R. Henn, President and Chief Scientific Officer of Seres Therapeutics (MCRB), received a grant of 75,000 derivative shares (reported as an award/acquisition) on March 4, 2026. The filing reports an acquisition at $0.00 per share (derivative award/option), meaning this is a compensatory grant rather than an open‑market purchase or sale.
Key Details
- Transaction date: 2026-03-04; Form 4 filed: 2026-03-06 (appears timely).
- Transaction type: Award/Grant of derivative securities (code A).
- Shares/units granted: 75,000 (reported at $0.00).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Vesting (footnote): 25% vests on March 2, 2027; the remainder vests in 12 equal quarterly installments thereafter.
- Remarks: Insider role listed as President and Chief Scientific Officer. No 10b5-1 plan, tax withholding, or immediate cashless sale was reported in the excerpt.
Context
This was a compensatory option/award grant that vests over time; the award does not represent immediate sale or purchase of shares. Such grants are common for executive compensation and represent potential future ownership as they vest and are (if applicable) exercised. This filing is informational and does not by itself indicate the insider’s current trading intent.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-03-04+75,000→ 75,000 totalExercise: $9.13Exp: 2036-03-03→ Common Stock (75,000 underlying)
Footnotes (1)
- [F1]The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter.